Advertisement

Patient-Derived Xenograft Models of Colorectal Cancer: Procedures for Engraftment and Propagation

  • Danielle M. Burgenske
  • David J. Monsma
  • Jeffrey P. MacKeigan
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1765)

Abstract

Preclinical compounds tested in animal models often demonstrate limited efficacy when transitioned into patients. As a result, individuals are assigned to treatment regimens that may be ineffective at treating their disease. The development of more clinically relevant models, such as patient-derived xenografts (PDXs), will (1) more completely mimic the human condition and (2) more accurately predict tumor responses to previously untested therapeutics.

PDX models are clinically relevant as tumor tissue is implanted directly from human donor to the mouse recipient. Therefore, these models prevent cell population selection, intentional or unintentional, as the human tissue adapts to an in vitro, two-dimensional environment prior to implantation into a three-dimensional in vivo murine host. Often, cell heterogeneity and tumor architecture can be maintained from human to the PDX model in the mouse. This protocol describes the engraftment and propagation processes for establishing colorectal (CRC) PDX models in mice, using tumor tissue from human subjects.

Key words

Tumor heterogeneity Preclinical in vivo efficacy Drug screening Colorectal cancer Patient-derived xenograft Tumorgraft 

References

  1. 1.
    Burgenske DM, Monsma DJ, Dylewski D, Scott SB, Sayfie AD, Kim DG, Luchtefeld M, Martin KR, Stephenson P, Hostetter G, Dujovny N, MacKeigan JP (2014) Establishment of genetically diverse patient-derived xenografts of colorectal cancer. Am J Cancer Res 4(6):824–837PubMedPubMedCentralGoogle Scholar
  2. 2.
    Monsma DJ, Cherba DM, Richardson PJ, Vance S, Rangarajan S, Dylewski D, Eugster E, Scott SB, Beuschel NL, Davidson PJ, Axtell R, Mitchell D, Lester EP, Junewick JJ, Webb CP, Monks NR (2014) Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer 61(9):1570–1577CrossRefPubMedGoogle Scholar
  3. 3.
    Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA, Borgman AS, Winn ME, Dykema KJ, Webb CP, MacKeigan JP, Duesbery NS, Nickoloff BJ, Monks NR (2015) Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am J Cancer Res 5(4):1507–1518PubMedPubMedCentralGoogle Scholar
  4. 4.
    Siolas D, Hannon GJ (2013) Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73(17):5315–5319CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Society AC (2017) Cancer Facts & Figures 2017Google Scholar
  6. 6.
    Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9(6):338–350CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Brown KM, Xue A, Mittal A, Samra JS, Smith R, Hugh TJ (2016) Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review. Oncotarget 7(40):66212–66225CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L (2011) A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1(6):508–523CrossRefPubMedGoogle Scholar
  10. 10.
    Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierre A, De The H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prevost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18(19):5314–5328CrossRefPubMedGoogle Scholar
  11. 11.
    Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 18(9):2515–2525CrossRefPubMedGoogle Scholar
  12. 12.
    Williams SA, Anderson WC, Santaguida MT, Dylla SJ (2013) Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Investig 93(9):970–982CrossRefPubMedGoogle Scholar
  13. 13.
    Puig I, Chicote I, Tenbaum SP, Arques O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espin E, Prat A, Elez ME, Argiles G, Vivancos A, Tabernero J, Rojas S, Palmer HG (2013) A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin Cancer Res 19(24):6787–6801CrossRefPubMedGoogle Scholar
  14. 14.
    Furukawa T, Kubota T, Watanabe M, Kuo TH, Nishibori H, Kase S, Saikawa Y, Tanino H, Teramoto T, Ishibiki K et al (1993) A metastatic model of human colon cancer constructed using cecal implantation of cancer tissue in nude mice. Surg Today 23(5):420–423CrossRefPubMedGoogle Scholar
  15. 15.
    Fu X, Herrera H, Kubota T, Hoffman RM (1992) Extensive liver metastasis from human colon cancer in nude and scid mice after orthotopic onplantation of histologically-intact human colon carcinoma tissue. Anticancer Res 12(5):1395–1397PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Danielle M. Burgenske
    • 1
  • David J. Monsma
    • 1
    • 2
  • Jeffrey P. MacKeigan
    • 1
    • 2
  1. 1.Center for Cancer Cell Biology, Van Andel Research InstituteGrand RapidsUSA
  2. 2.College of Human MedicineMichigan State UniversityGrand RapidsUSA

Personalised recommendations